Literature DB >> 15685439

Epidemiology and etiology of gliomas.

Hiroko Ohgaki1, Paul Kleihues.   

Abstract

Gliomas of astrocytic, oligodendroglial and ependymal origin account for more than 70% of all brain tumors. The most frequent (65%) and most malignant histological type is the glioblastoma. Since the introduction of computerized tomography and magnetic resonance imaging, the incidence rates of brain tumors have been rather stable, with a tendency of higher rates in highly developed, industrialized countries. Some reports indicate that Caucasians have higher incidence than black or Asian populations, but to some extent, this may reflect socio-economic differences and under-ascertainment in some regions, rather than a significant difference in genetic susceptibility. With the exception of pilocytic astrocytomas, the prognosis of glioma patients is still poor. Less than 3% of glioblastoma patients are still alive at 5 years after diagnosis, higher age being the most significant predictor of poor outcome. Brain tumors are a component of several inherited tumor syndromes, but the prevalence of these syndromes is very low. Several occupations, environmental carcinogens, and diet (N-nitroso compounds) have been reported to be associated with an elevated glioma risk, but the only environmental factor unequivocally associated with an increased risk of brain tumors, including gliomas, is therapeutic X-irradiation. In particular, children treated with X-irradiation for acute lymphoblastic leukemia show a significantly elevated risk of developing gliomas and primitive neuroectodermal tumor (PNET), often within 10 years after therapy. TP53 mutations are frequent in low-grade gliomas and secondary glioblastomas derived therefrom. Approximately 60% of mutations are located in the hot spot codons 248 and 273, and the majority of these are G:C-->A:T transitions at CpG sites. TP53 mutations are significantly more frequent in low-grade astrocytomas with promoter methylation of the O(6)-methylguanine-DNA methyltransferase repair gene, suggesting that, in addition to deamination of 5-methylcytosine, exogenous or endogenous alkylation in the O(6) position of guanine may contribute to the formation of these mutations.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15685439     DOI: 10.1007/s00401-005-0991-y

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  454 in total

1.  Clinical significance of Polycomb gene expression in brain tumors.

Authors:  Francesco Crea; Elaine M Hurt; William L Farrar
Journal:  Mol Cancer       Date:  2010-09-30       Impact factor: 27.401

2.  High β-catenin/Tcf-4 activity confers glioma progression via direct regulation of AKT2 gene expression.

Authors:  Junxia Zhang; Kai Huang; Zhendong Shi; Jian Zou; Yingyi Wang; Zhifan Jia; Anling Zhang; Lei Han; Xiao Yue; Ning Liu; Tao Jiang; Yongping You; Peiyu Pu; Chunsheng Kang
Journal:  Neuro Oncol       Date:  2011-06       Impact factor: 12.300

3.  Possible association between genetic variants in the H2AFX promoter region and risk of adult glioma in a Chinese Han population.

Authors:  Weiwei Fan; Keke Zhou; Yingjie Zhao; Wenting Wu; Hongyan Chen; Li Jin; Gong Chen; Jinlong Shi; Qingyi Wei; Tianbao Zhang; Guhong Du; Ying Mao; Daru Lu; Liangfu Zhou
Journal:  J Neurooncol       Date:  2011-04-22       Impact factor: 4.130

4.  Increased expression of FAT10 is correlated with progression and prognosis of human glioma.

Authors:  Jun Yuan; Yanyang Tu; Xinggang Mao; Shiming He; Liang Wang; Guoqiang Fu; Jianhai Zong; Yongsheng Zhang
Journal:  Pathol Oncol Res       Date:  2012-03-09       Impact factor: 3.201

5.  Establishing cut-off points with clinical relevance for bcl-2, cyclin D1, p16, p21, p27, p53, Sox11 and WT1 expression in glioblastoma - a short report.

Authors:  Emma Camacho-Urkaray; Jorge Santos-Juanes; Francisco Borja Gutiérrez-Corres; Beatriz García; Luis M Quirós; Isabel Guerra-Merino; José Javier Aguirre; Iván Fernández-Vega
Journal:  Cell Oncol (Dordr)       Date:  2017-12-07       Impact factor: 6.730

6.  Prognostic factors for survival in 676 consecutive patients with newly diagnosed primary glioblastoma.

Authors:  Graziella Filippini; Chiara Falcone; Amerigo Boiardi; Giovanni Broggi; Maria G Bruzzone; Dario Caldiroli; Rita Farina; Mariangela Farinotti; Laura Fariselli; Gaetano Finocchiaro; Sergio Giombini; Bianca Pollo; Mario Savoiardo; Carlo L Solero; Maria G Valsecchi
Journal:  Neuro Oncol       Date:  2007-11-09       Impact factor: 12.300

7.  Association of BCL2-938C>A genetic polymorphism with glioma risk in Chinese Han population.

Authors:  Wei Li; Chunfa Qian; Linxiong Wang; Hong Teng; Li Zhang
Journal:  Tumour Biol       Date:  2013-11-28

8.  Epidemiology of glioma: clinical characteristics, symptoms, and predictors of glioma patients grade I-IV in the the Danish Neuro-Oncology Registry.

Authors:  Birthe Krogh Rasmussen; Steinbjørn Hansen; René J Laursen; Michael Kosteljanetz; Henrik Schultz; Bente Mertz Nørgård; Rikke Guldberg; Kim Oren Gradel
Journal:  J Neurooncol       Date:  2017-08-31       Impact factor: 4.130

9.  Adding 11C-methionine PET to the EORTC prognostic factors in grade 2 gliomas.

Authors:  A Smits; E Westerberg; D Ribom
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-08-21       Impact factor: 9.236

10.  Low HER2-expressing glioblastomas are more often secondary to anaplastic transformation of low-grade glioma.

Authors:  Jean-François Mineo; Anne Bordron; Marc Baroncini; Claude-Alain Maurage; Carole Ramirez; Rose-Mary Siminski; Christian Berthou; Phong Dam Hieu
Journal:  J Neurooncol       Date:  2007-06-15       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.